The efficacy and safety of paclitaxel and carboplatin with versus without bevacizumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis.

The efficacy and safety of paclitaxel and carboplatin with versus without bevacizumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2018 Mar 06;9(18):14619-14629 Authors: Han S, Hong Y, Liu T, Wu N, Ye Z Abstract Objectives: To investigate the efficacy and safety of Bevacizumab (Bev) used in combination with paclitaxel and carboplatin (PC), compared with PC alone in patients with advanced non-small-cell lung cancer (NSCLC). Materials and Methods: We searched the PubMed, EMBASE, Cochrane Central Register of Controlled Trials and Chinese Biomedical Literature electronic databases, to identify randomized controlled trials of PC plus Bev versus PC alone for the treatment of NSCLC. The meta-analysis was performed using Reviewer Manager Version 5.3 software provided by the Cochrane Collaboration. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), objective response rate (ORR), the incidence of severe adverse events and treatment-related deaths. Results: The final analysis included 5 trials with a total of 1486 patients. Compared with PC alone, the regimen of PC plus Bev resulted in significantly longer PFS (HR = 0.57; 95% CI = 0.46 to 0.71; p
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Related Links:

Authors: Khan MY, Pandit S, Jayagopal PB, Oomman A, Chockalingam KC, Ramakrishnan A, Mane A, Mehta S, Shah S Abstract Background: Real-world data on the effectiveness of antihypertensive drugs (AHDs) in India is limited. The present study aims to provide updated evidence regarding the effectiveness of olmesartan as monotherapy or in combination with other AHDs in Indian patients with essential hypertension. Methods: Electronic medical record data of adult patients who were diagnosed with essential hypertension (≥140/90 mmHg) and were prescribed olmesartan as mono- or add-on therapy were retrospectively analy...
Source: Journal of the Association of Physicians of India - Category: General Medicine Tags: J Assoc Physicians India Source Type: research
Conclusions: Proteins are very effectively associated with liposomes via a GPI -anchor to form proteoliposome particles and these are useful for a variety of applications including vaccines and antibody-mediated targeting of liposomes. Importantly, the CHO-cell and GPI-tagged produced PfRH5 elicited invasion-blocking antibodies qualitatively comparable to other approaches.
Source: Journal of Venomous Animals and Toxins including Tropical Diseases - Category: Tropical Medicine Source Type: research
CONCLUSION: The video laryngoscope occupies a prominent position in cases in which access to the airway is difficult. In the present case it was useful. It can be used as first choice or as a rescue technique. The video laryngoscope is an appropriate alternative and should be available for facing the ever-challenging difficult airway patient. PMID: 32736863 [PubMed - as supplied by publisher]
Source: Revista Brasileira de Anestesiologia - Category: Anesthesiology Tags: Rev Bras Anestesiol Source Type: research
V FOUNDATION FINDS A WAY: Even amid Covid-19, the V Foundation for Cancer Research is getting the word out about its mission. The organization is teaming with ESPN for “V for Victory,” a one-hour television special hosted by ESPN’s Kevin Negandhi and Hannah Storm, on Aug. 8 at 2 p.m. EST on ABC as part of the Wine Celebration’s 2020 virtual event. The idea is to shine a light on cancer survivor stories and the urgency to support cancer research during the pandemic and support the V Foundation’s…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Madison-based Exact Sciences increases investment in Thrive Earlier Detection Corp.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
This study describes the treatment patterns, effectiveness, and safety profile of Pem-Pt + Bev in patients with NS-NSCLC in China in clinical practice. METHODS: Data from eligible patients with advanced NS-NSCLC who received Pem-Pt with (136 patients) or without (97 patients) bevacizumab from January 2012 to March 2017 were retrospectively evaluated. The effectiveness outcomes included the assessment of progression-free survival (PFS) and objective response rate (ORR) in the overall population, the percentage of patients with pleural effusion or brain metastasis, as well as the percentage of patients receivi...
Source: Clinical Therapeutics - Category: Drugs & Pharmacology Authors: Tags: Clin Ther Source Type: research
CONCLUSIONSAll 3 regimens were feasible for patients with advanced NSCLC and an ECOG performance status of 2. The addition of bevacizumab to pemetrexed increased the overall response rate. The efficacy of pemetrexed/carboplatin/bevacizumab (median PFS, 4.8 months) approached the prespecified study PFS goal of 5 months. Larger studies will be necessary to define the role of bevacizumab in addition to standard pemetrexed and carboplatin in this population. Cancer 2018. © 2018 American Cancer Society.
Source: Cancer - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research
ConclusionsThe addition of bevacizumab to erlotinib prolonged progression-free survival inEGFR mutation-positive NSCLC. Follow-up safety data were consistent with the known safety profiles of both erlotinib and bevacizumab in NSCLC; this combination appeared to be manageable, and treatment was well tolerated.JapicCTI-111390.
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research
Authors: Losanno T, Gridelli C Abstract Introduction - Lung cancer still represents the leading cause of death for cancer. About the 70% of diagnosis are in advanced-stage. Non-small-cell lung cancer (NSCLC) represents the 85% of all diagnosed lung cancers and non-squamous histology represents the 40% of all NSCLC. First-line therapies increase survival, control symptoms and improve quality of life, compared with best supportive care. It is crucial to choose a treatment with a low impact on patient's life considering the related toxicities. Areas covered - Adverse events (AEs) of first-line therapies for non-squamo...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
Vascular endothelial growth factor (VEGF) plays the most important role in regulating tumor-related angiogenesis and is often highly expressed in human cancers making it a preferred target for antitumor therapy [1,2]. With the introduction of VEGF inhibitors for cancer treatment, new class-specific adverse events (AEs) for these drugs have been observed, including perforations, bleeding, thromboembolic events, hypertension, and proteinuria [3,4]. Skin-related AEs are also often associated with the anti-VEGF small-molecule tyrosine kinase inhibitors sorafenib and sunitinib although these effects are not related directly to ...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Avastin | Bleeding | Cancer | Cancer & Oncology | China Health | Databases & Libraries | Hypertension | Lung Cancer | Non-Small Cell Lung Cancer | Proteinuria | Toxicology